UAE makes history with approval of groundbreaking oral vitiligo treatment

At the Emirates Dermatology Conference in Dubai, the nation becomes the first globally to approve an innovative therapeutic breakthrough, underscoring its emergence as a hub for pharmaceutical innovation and advanced healthcare.

The tenth Emirates Dermatology Conference opened this week at the InterContinental Dubai, drawing more than five hundred physicians and specialists from around the world to explore the frontiers of skin medicine. Against the backdrop of advanced scientific lectures, hands-on workshops and live clinical demonstrations, the gathering has witnessed a moment of quiet but significant achievement: the announcement that the United Arab Emirates has become the first country globally to approve an innovative oral treatment for vitiligo, a condition affecting millions.

Dr. Ayman Alnaeem, President of the Emirates Dermatology Society and conference chair, positioned the approval as emblematic of the nation’s broader commitment to rapid pharmaceutical innovation and access to advanced therapies. The landmark treatment will be formally launched during the conference, alongside a portfolio of new dermatological medicines including the latest generation of biological treatments for psoriasis. Such speed in medicine registration, Dr. Alnaeem noted, reflects the UAE’s standing among the world’s fastest countries in bringing new treatments to patients.

The three-day conference addresses the full spectrum of contemporary dermatology: skin ageing, eczema, acne, skin cancer and inflammatory conditions. The scientific programme emphasises emerging technologies, particularly the application of artificial intelligence to diagnose conditions such as psoriasis and skin cancer, and the refinement of laser therapies for vascular birthmarks, pigmentation and benign tumours. This commitment to technological advancement positions dermatological care at the intersection of innovation and clinical excellence.

Among the conference’s distinctive educational offerings is the fifth edition of the Residents’ Academy, a specialised platform designed to prepare the next generation of dermatology leaders through hands-on training, professional mentorship and essential knowledge transfer. Dr. Alnaeem emphasised the importance of creating sustainable pathways for continuous professional development, whether for established practitioners or those beginning their careers in the field.

The conference has also marked Dubai’s formal submission of a bid to host the World Congress of Dermatology in 2031. Dr. Jawaher Al Naqbi, heading the bid committee, noted that five global cities are competing for the honour, yet described Dubai’s prospects as exceptionally strong given the city’s distinctive infrastructure and the nation’s demonstrated achievements in dermatological innovation and care. The bid reflects not merely geographical advantage but a comprehensive vision for the future of global dermatological advancement.

What it means for Abu Dhabi

The approval of this novel oral vitiligo treatment exemplifies the UAE’s broader position as a centre for medical innovation and patient access to cutting-edge therapies. Abu Dhabi’s health sector continues to benefit from the nation’s commitment to rapid pharmaceutical registration and the adoption of advanced diagnostic and therapeutic technologies. This leadership in dermatology mirrors the emirate’s wider investments in healthcare excellence and innovation infrastructure.

The success of this year’s Emirates Dermatology Conference, bringing five hundred global specialists to share knowledge and research findings, reinforces Abu Dhabi and the broader UAE’s role as a destination for scientific exchange and medical advancement. Such gatherings strengthen the nation’s position as a hub where physicians, researchers and industry leaders converge to advance the standards of care available to patients across the region and beyond.

Source: WAM

On Simply Luxury: InterContinental